Search hospitals > Tennessee > Nashville
Sarah Cannon Cancer Center
Claim this profileNashville, Tennessee 37203
Global Leader in Cancer
Global Leader in Solid Tumors
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
219 reported clinical trials
15 medical researchers
Summary
Sarah Cannon Cancer Center is a medical facility located in Nashville, Tennessee. This center is recognized for care of Cancer, Solid Tumors, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer and other specialties. Sarah Cannon Cancer Center is involved with conducting 219 clinical trials across 178 conditions. There are 15 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Gerald Falchook, MD, and Meredith A McKean.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
FGFR3 positive
2Solid Tumors
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute6 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
66 reported clinical trials
94 drugs studied
Erika P HamiltonSarah Cannon Research Institute5 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
55 reported clinical trials
77 drugs studied
Gerald Falchook, MDSarah Cannon Research Institute at HealthONE6 years of reported clinical research
Expert in Solid Tumors
Expert in Cancer
40 reported clinical trials
61 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Solid Tumors
Expert in Cystic Tumor
35 reported clinical trials
67 drugs studied
Clinical Trials running at Sarah Cannon Cancer Center
Cancer
Solid Tumors
Breast Cancer
Lung Cancer
Colorectal Cancer
Endometrial Cancer
Pancreatic Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Breast cancer
Sotorasib
for Solid Cancers
This trial is testing a medication called sotorasib. It is aimed at adults who have advanced solid tumors with a specific genetic mutation known as KRAS p.G12C. Sotorasib works by blocking this mutation, which can help slow down or stop the growth of the cancer. Sotorasib is the first targeted agent approved for this specific mutation in patients who have previously received treatment.
Recruiting1 award Phase 12 criteria
AMT-116
for Cancer
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors
Recruiting1 award Phase 14 criteria
AB801
for Advanced Cancer
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Recruiting1 award Phase 19 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sarah Cannon Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.